Literature DB >> 1416826

Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.

W C Hellinger1, M S Rouse, P M Rabadan, N K Henry, J M Steckelberg, W R Wilson.   

Abstract

We studied the efficacy of continuous intravenous infusion of ampicillin compared with that of intermittent administration of ampicillin alone or in combination with gentamicin for the therapy of highly aminoglycoside-resistant enterococcal experimental endocarditis. Rabbits were infected with a gentamicin-susceptible (MIC, 256 micrograms/ml) strain of Enterococcus faecalis or a strain of E. faecalis which was highly resistant to gentamicin in vitro (MIC, greater than 2,000 micrograms/ml). Administration of ampicillin by continuous intravenous infusion did not significantly enhance the killing of enterococci in vivo compared with that by intermittent administration of ampicillin for either the aminoglycoside-susceptible or the aminoglycoside-resistant strain. In combination with gentamicin, there were no significant differences in efficacies obtained with intermittent versus continuous intravenous infusion of ampicillin therapy for experimental endocarditis caused by either strain of E. faecalis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416826      PMCID: PMC190330          DOI: 10.1128/AAC.36.6.1272

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Treatment of bacterial endocarditis.

Authors:  M FINLAND
Journal:  N Engl J Med       Date:  1954-03-04       Impact factor: 91.245

2.  Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study.

Authors:  M J Zervos; C A Kauffman; P M Therasse; A G Bergman; T S Mikesell; D R Schaberg
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

3.  Penetration of antibiotics into fibrin loci in vivo. 3. Intermittent vs. continuous infusion and the effect of probenecid.

Authors:  M Barza; J Brusch; M G Bergeron; L Weinstein
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

4.  Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center.

Authors:  G L Mandell; D Kaye; M E Levison; E W Hook
Journal:  Arch Intern Med       Date:  1970-02

5.  Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance.

Authors:  C A Spiegel; M Huycke
Journal:  Arch Intern Med       Date:  1989-08

6.  In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.

Authors:  L B Rice; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis.

Authors:  M Ingerman; P G Pitsakis; A Rosenberg; M T Hessen; E Abrutyn; B E Murray; M E Levison
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

8.  Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats.

Authors:  C Thauvin; G M Eliopoulos; S Willey; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Plasmid-mediated resistance to aminocyclitol antibiotics in group D streptococci.

Authors:  P Courvalin; C Carlier; E Collatz
Journal:  J Bacteriol       Date:  1980-08       Impact factor: 3.490

10.  Aortic endocarditis caused by gentamicin-resistant Enterococcus faecalis.

Authors:  M L Fernández-Guerrero; C Barros; J L Rodriguez Tudela; R Fernández Roblas; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

View more
  4 in total

1.  Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.

Authors:  R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

Authors:  D P Nicolau; M N Marangos; C H Nightingale; K B Patel; B W Cooper; R Quintiliani; P Courvalin; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.

Authors:  J Gavaldà; C Torres; C Tenorio; P López; M Zaragoza; J A Capdevila; B Almirante; F Ruiz; N Borrell; X Gomis; C Pigrau; F Baquero; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

4.  Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.

Authors:  S R Lavoie; E S Wong; P E Coudron; D S Williams; S M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.